Table 2. A summary of the biodistribution data for 89Zr-atezo and 89Zr-C4 in tumor bearing mice at 48 hours post injection.
Immunocompetent intact male C57Bl/6J mice were inoculated subcutaneously with B16F10 in the flank, and immunocompromised athymic male nu/nu mice received subcutaneous H1975 tumors in the flank. C4 uptake in normal tissues was generally lower that atezo, with the notable exception of the liver and kidney. Abbreviations: Lg. Int. = large intestine, Sm. Int. = small intestine, N/A = not applicable. The specific activity of 89Zr-atezo was 1.53 μCi/μg (B16 F10) and 2.17 μCi/μg (H1975). The specific activity of 89Zr-C4 was previously determined to be 7 μCi/μg.
| Tissue | 89Zr-atezo | 89Zr-C4 | 89Zr-atezo | 89Zr-C4 |
|---|---|---|---|---|
| Blood | 2.87 ± 0.4 | 2.17 ± 0.3 | 1.02 ± 0.2 | 2.87 ± 0.6 |
| Heart | 3.93 ± 0.3 | 0.96 ± 0.05 | 1.85 ± 0.3 | 1.08 ± 0.1 |
| Lung | 8.59 ± 0.8 | 0.89 ± 0.1 | 5.53 ± 0.9 | 1.79 ± 0.3 |
| Liver | 6.79 ± 1.6 | 7.33 ± 1.1 | 3.15 ± 0.5 | 8.16 ± 0.6 |
| Kidney | 6.71 ± 0.3 | 2.76 ± 0.8 | 3.60 ± 0.4 | 4.28 ± 0.7 |
| Spleen | 19.95 ± 1.5 | 6.05 ± 0.2 | 15.51 ± 1.6 | 6.48 ± 1.0 |
| Pancreas | 1.85 ± 0.2 | 0.49 ± 0.01 | 1.03 ± 0.07 | 0.57 ± 0.06 |
| Lg. Int. | 2.83 ± 0.3 | 0.68 ± 0.3 | 1.57 ± 0.2 | 0.51 ± 0.1 |
| Sm. Int. | 6.44 ± 0.5 | 0.59 ± 0.1 | 3.59 ± 0.6 | 0.73 ± 0.3 |
| Stomach | 1.75 ± 0.5 | 0.36 ± 0.1 | 0.89 ± 0.2 | 0.44 ± 0.1 |
| Muscle | 1.63 ± 0.6 | 0.73 ± 0.3 | 0.82 ± 0.07 | 0.47 ± 0.06 |
| Bone | 7.11 ± 1.64 | 2.62 ± 0.3 | 3.31 ± 0.8 | 2.87 ± 0.3 |
| Brain | 0.33 ± 0.02 | 0.27 ± 0.1 | 0.14 ± 0.08 | 0.16 ± 0.02 |
| B16 F10 | 13.92 ± 1.0 | 13.83 ± 0.5 | N/A | N/A |
| H1975 | N/A | N/A | 3.97±1.0 | 7.08±0.8 |